Published in Respir Med on July 15, 2012
Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. J Thorac Cardiovasc Surg (2014) 1.64
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 0.84
Diagnosis and management of interstitial lung disease. Transl Respir Med (2014) 0.83
Content validity of CASA-Q cough domains and UCSD-SOBQ for use in patients with Idiopathic Pulmonary Fibrosis. Glob J Health Sci (2013) 0.79
Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med (2013) 0.78
Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Curr Respir Med Rev (2016) 0.75
The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Can Respir J (2016) 0.75
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes (2003) 3.42
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res (2000) 2.65
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest (1998) 2.57
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res (1992) 1.79
Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol (2003) 1.75
Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes (2005) 1.69
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax (2005) 1.64
Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med (2005) 1.51
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J (2009) 1.51
Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med (2009) 1.47
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax (2009) 1.46
Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest (2000) 1.37
Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest (2005) 1.36
Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Care (2000) 1.35
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14
Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit (2002) 1.02
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med (2008) 4.33
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg (2014) 4.19
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care (2007) 3.53
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66
Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med (2008) 2.65
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med (2011) 2.62
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2006) 2.60
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2009) 2.58
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.50
Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 2.43
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (2003) 2.41
Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med (2006) 2.34
Economic return of clinical trials performed under the pediatric exclusivity program. JAMA (2007) 2.28
Quality of life in long-term cervical cancer survivors. Gynecol Oncol (2005) 2.22
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Autoimmune-featured interstitial lung disease: a distinct entity. Chest (2011) 2.20
Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest (2002) 2.19
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med (2008) 2.15
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest (2015) 2.02
Idiopathic pleuroparenchymal fibroelastosis: description of a novel clinicopathologic entity. Chest (2004) 2.00
A prospective multicenter study of competency metrics and educational interventions in the learning of bronchoscopy among new pulmonary fellows. Chest (2009) 1.97
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med (2005) 1.90
Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest (2011) 1.85
Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease. J Pediatr Gastroenterol Nutr (2013) 1.82
Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med (2013) 1.81
A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med (2011) 1.81
A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology (2010) 1.80
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2014) 1.80
Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2004) 1.80
The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One (2013) 1.78
Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol (2007) 1.78
Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax (2013) 1.77
Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest (2006) 1.76
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Aff (Millwood) (2008) 1.74
Emergency department crowding is associated with decreased quality of care for children with acute asthma. Ann Emerg Med (2011) 1.73
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2005) 1.69
Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol (2011) 1.68
Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest (2007) 1.66
The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Med Care (2006) 1.65
Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest (2008) 1.65
Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population. Cancer Epidemiol Biomarkers Prev (2012) 1.65
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med (2010) 1.64
Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2004) 1.62
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest (2005) 1.60
A generalized estimator of the attributable benefit of an optimal treatment regime. Biometrics (2009) 1.58
Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One (2009) 1.56
Views of potential subjects toward proposed regulations for clinical research with adults unable to consent. Am J Psychiatry (2002) 1.55
Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol (2009) 1.55
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54